Detalhe da pesquisa
1.
Immune-mediated thrombocytopenia and IL-6-mediated thrombocytosis observed in idiopathic multicentric Castleman disease.
Br J Haematol
; 204(3): 921-930, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38168727
2.
Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease.
Haematologica
; 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38205523
3.
Increased mTORC2 pathway activation in lymph nodes of iMCD-TAFRO.
J Cell Mol Med
; 26(11): 3147-3152, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35488725
4.
The disease course of Castleman disease patients with fatal outcomes in the ACCELERATE registry.
Br J Haematol
; 198(2): 307-316, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35507638
5.
Increased mTOR activation in idiopathic multicentric Castleman disease.
Blood
; 135(19): 1673-1684, 2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32206779
6.
Bone marrow findings of idiopathic Multicentric Castleman disease: A histopathologic analysis and systematic literature review.
Hematol Oncol
; 40(2): 191-201, 2022 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-35104370
7.
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease.
Am J Hematol
; 96(10): 1241-1252, 2021 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34265103
8.
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Blood
; 132(20): 2115-2124, 2018 11 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181172
9.
Predictors of response to anti-IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data.
Br J Haematol
; 184(2): 232-241, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30203839
10.
Siltuximab administration results in spurious IL-6 elevation in peripheral blood.
Am J Hematol
; 99(1): E15-E18, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37867418
11.
Plasma proteomics identifies a 'chemokine storm' in idiopathic multicentric Castleman disease.
Am J Hematol
; 93(7): 902-912, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29675946
12.
Ongoing symptoms following complete surgical excision in unicentric Castleman disease.
Am J Hematol
; 98(11): E334-E337, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37635628
13.
Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes.
Blood Adv
; 7(21): 6652-6664, 2023 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37656441
14.
Idiopathic Multicentric Castleman Disease Occurring Shortly after mRNA SARS-CoV-2 Vaccine.
Vaccines (Basel)
; 10(10)2022 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36298590
15.
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease.
Nat Commun
; 13(1): 7236, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36433996
16.
Emerging role of 18F-FDG PET/CT in Castleman disease: a review.
Insights Imaging
; 12(1): 35, 2021 Mar 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33709329
17.
Discovery and validation of a novel subgroup and therapeutic target in idiopathic multicentric Castleman disease.
Blood Adv
; 5(17): 3445-3456, 2021 09 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-34438448
18.
Type I IFN response associated with mTOR activation in the TAFRO subtype of idiopathic multicentric Castleman disease.
JCI Insight
; 5(9)2020 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32376796
19.
Treatments Administered to the First 9152 Reported Cases of COVID-19: A Systematic Review.
Infect Dis Ther
; 9(3): 435-449, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32462545
20.
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder.
Cell Rep Med
; 1(9): 100158, 2020 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-33377129